PT - JOURNAL ARTICLE AU - Liu, Aoxing AU - Genovese, Giulio AU - Zhao, Yajie AU - Pirinen, Matti AU - Zekavat, Maryam M. AU - Kentistou, Katherine AU - Yang, Zhiyu AU - Yu, Kai AU - Vlasschaert, Caitlyn AU - Liu, Xiaoxi AU - Brown, Derek W. AU - Hudjashov, Georgi AU - Gorman, Bryan AU - Dennis, Joe AU - Zhou, Weiyin AU - Momozawa, Yukihide AU - Pyarajan, Saiju AU - Tuzov, Vlad AU - Pajuste, Fanny-Dhelia AU - Aavikko, Mervi AU - Sipilä, Timo P. AU - Ghazal, Awaisa AU - Huang, Wen-Yi AU - Freedman, Neal AU - Song, Lei AU - Gardner, Eugene J. AU - FinnGen AU - BCAC AU - MVP AU - Sankaran, Vijay G. AU - Palotie, Aarno AU - Ollila, Hanna M. AU - Tukiainen, Taru AU - Chanock, Stephen J. AU - Mägi, Reedik AU - Natarajan, Pradeep AU - Daly, Mark J. AU - Bick, Alexander AU - McCarroll, Steven A. AU - Terao, Chikashi AU - Loh, Po-Ru AU - Ganna, Andrea AU - Perry, John R.B. AU - Machiela, Mitchell J. TI - Population analyses of mosaic X chromosome loss identify genetic drivers and widespread signatures of cellular selection AID - 10.1101/2023.01.28.23285140 DP - 2023 Jan 01 TA - medRxiv PG - 2023.01.28.23285140 4099 - http://medrxiv.org/content/early/2023/01/31/2023.01.28.23285140.short 4100 - http://medrxiv.org/content/early/2023/01/31/2023.01.28.23285140.full AB - Mosaic loss of the X chromosome (mLOX) is the most commonly occurring clonal somatic alteration detected in the leukocytes of women, yet little is known about its genetic determinants or phenotypic consequences. To address this, we estimated mLOX in >900,000 women across eight biobanks, identifying 10% of women with detectable X loss in approximately 2% of their leukocytes. Out of 1,253 diseases examined, women with mLOX had an elevated risk of myeloid and lymphoid leukemias and pneumonia. Genetic analyses identified 49 common variants influencing mLOX, implicating genes with established roles in chromosomal missegregation, cancer predisposition, and autoimmune diseases. Complementary exome-sequence analyses identified rare missense variants in FBXO10 which confer a two-fold increased risk of mLOX. A small fraction of these associations were shared with mosaic Y chromosome loss in men, suggesting different biological processes drive the formation and clonal expansion of sex chromosome missegregation events. Allelic shift analyses identified alleles on the X chromosome which are preferentially retained, demonstrating that variation at many loci across the X chromosome is under cellular selection. A novel polygenic score including 44 independent X chromosome allelic shift loci correctly inferred the retained X chromosomes in 80.7% of mLOX cases in the top decile. Collectively our results support a model where germline variants predispose women to acquiring mLOX, with the allelic content of the X chromosome possibly shaping the magnitude of subsequent clonal expansion.Competing Interest StatementG.G., P.-R.L., and S.A.M. declare competing interests: patent application PCT/WO2019/079493 has been filed on the mosaic chromosomal alterations detection method used in this work. J.R.B.P and E.J.G are employee of and hold shares in Adrestia Therapeutics. A.B. reports scientific advisory board membership for TenSixteen Bio. P.N. reports grant support from Apple, Amgen, Boston Scientific, AstraZeneca, and Novartis, personal fees from Apple, AstraZeneca, Blackstone Life Sciences, Foresite Labs, Genentech/Roche, Allelica, Novartius, scientific advisory board membership for geneXwell, Esperion Therapeutics, and TenSixteen Bio, is a scientific co-founder of TenSixteen Bio, and spousal employment at Vertex, all unrelated to the present study.Funding StatementThis work was supported by the Intramural Research Program of the National Cancer Institute, National Institutes of Health, and the Medical Research Council (unit programs: MC_UU_12015/2, MC_UU_00006/2). G.G. was supported by NIH grants R01 MH104964 and R01 MH123451. A.G. was supported by the Academy of Finland (grant no. 323116) and by the European Research Council under the European Union's Horizon 2020 Research and Innovation Programme (grant no. 945733). P.-R.L. was supported by NIH grant DP2 ES030554, a Burroughs Wellcome Fund Career Award at the Scientific Interfaces, the Next Generation Fund at the Broad Institute of MIT and Harvard, and a Sloan Research Fellowship. C.T. was supported by Japan Agency for Medical Research and Development (AMED) grants JP21kk0305013, JP21tm0424220, and JP21ck0106642, and Japan Society for the Promotion of Science (JSPS) KAKENHI grant JP20H00462.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The FinnGen study is approved by Finnish Institute for Health and Welfare (permit numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019 and THL/1524/5.05.00/2020), Digital and population data service agency (permit numbers: VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, KELA 134/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA 16/522/2020), Findata permit numbers THL/2364/14.02/2020, THL/4055/14.06.00/2020,,THL/3433/14.06.00/2020, THL/4432/14.06/2020, THL/5189/14.06/2020, THL/5894/14.06.00/2020, THL/6619/14.06.00/2020, THL/209/14.06.00/2021, THL/688/14.06.00/2021, THL/1284/14.06.00/2021, THL/1965/14.06.00/2021, THL/5546/14.02.00/2020, THL/2658/14.06.00/2021, THL/4235/14.06.00/202, Statistics Finland (permit numbers: TK-53-1041-17 and TK/143/07.03.00/2020 (earlier TK-53-90-20) TK/1735/07.03.00/2021, TK/3112/07.03.00/2021) and Finnish Registry for Kidney Diseases permission/extract from the meeting minutes on 4th July 2019. The UKBB analyses were conducted using applications 7089, 9905, and 21552.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary statistics generated from meta-analysis will be uploaded to GWAS Catalog after publication. Individual level data can be requested directly from each contributing biobank.